Cargando…

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Bo, Liu, Delong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734251/ https://www.ncbi.nlm.nih.gov/pubmed/31500657 http://dx.doi.org/10.1186/s13045-019-0786-6

Ejemplares similares

Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
por: Yu, Bo, et al.
Publicado: (2019)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
por: Liu, Delong, et al.
Publicado: (2019)

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
por: Hartley-Brown, Monique, et al.
Publicado: (2022)

Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
por: Ray, Upasana, et al.
Publicado: (2023)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Recent updates on CAR T clinical trials for multiple myeloma
por: Lin, Quande, et al.
Publicado: (2019)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
por: Nerone, Marta, et al.
Publicado: (2022)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
por: Abrahams, Cristina L., et al.
Publicado: (2018)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

Exploration of the antibody–drug conjugate clinical landscape
por: Maecker, Heather, et al.
Publicado: (2023)

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
por: Jain, Salvia, et al.
Publicado: (2011)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Antibody-Based Therapies in Multiple Myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2011)

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma
por: Ketchum, Emily Behren, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma
por: Kapinos, Kandice A., et al.
Publicado: (2023)

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
por: Caraccio, Chiara, et al.
Publicado: (2020)

Recent advances of antibody drug conjugates for clinical applications
por: Zhao, Pengxuan, et al.
Publicado: (2020)

Frontline therapies for untreated chronic lymphoid leukemia
por: Liu, Delong, et al.
Publicado: (2019)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
por: Dan, Nirnoy, et al.
Publicado: (2018)

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
por: Barreca, Marilia, et al.
Publicado: (2022)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Methods for site-specific drug conjugation to antibodies
por: Behrens, Christopher R, et al.
Publicado: (2014)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
por: Gogia, Pooja, et al.
Publicado: (2023)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nb22edfd30d8h6hpsdajp8jlku